Stay updated on A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH website transition updates and says federal agencies are shifting terminology from “Artificial Intelligence” to “Super Intelligence.”
    Difference
    1%
    Check dated 2026-10-26T15:22:09.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-19T15:59:56.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-12T15:58:52.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The study record page displays a 403 Forbidden message and a Home link instead of the record content.
    Difference
    0.5%
    Check dated 2026-10-05T18:20:53.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    403 Forbidden error page is now displayed for the study record, with the 403 heading, basic site navigation, and footer visible. The page appears to replace the study content due to access restrictions.
    Difference
    18%
    Check dated 2026-09-21T22:17:14.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    Revision updated from v3.6.5 to v3.6.6, reflecting a minor page update.
    Difference
    0.1%
    Check dated 2026-08-31T16:45:58.000Z thumbnail image

Stay in the know with updates to A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.